<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182103</url>
  </required_header>
  <id_info>
    <org_study_id>NSC99-2628-B-182-002-MY2</org_study_id>
    <nct_id>NCT01182103</nct_id>
  </id_info>
  <brief_title>Epigenetic Regulation of BDNF in Major Depression</brief_title>
  <official_title>Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will (1) detect the associations between brain-derived neurotrophic factor
      (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and
      antidepressant responses in major depressive disorder (MDD) patients, (2) check the
      correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and (3) discuss the
      possible mechanisms of epigenetic regulation of BDNF in Taiwanese major depressive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain-derived neurotrophic factor (BDNF) had been chosen as a candidate gene for a
      development of major depressive disorder (MDD). BDNF had been reported to have an important
      role on neuronal plasticity, axonal growth and connectivity, and participating in the local
      response to various types of neuronal stressors. BDNF also influences the differentiation of
      neurons.

      In the past studies, the investigators had found that major depressive women had lower serum
      BDNF protein levels than healthy controls, and their BDNF levels became significantly
      increased after antidepressant treatments. In addition, some authors had found that reduced
      expression of BDNF was noted in postmortem brain of completed suicide subjects. Suicidal
      major depressive patients also had lower plasma BDNF levels than non-suicidal major
      depressive patients. These findings suggested that BDNF might play an important role in the
      suicidal behavior.

      However, in past studies, the results did not fully explain why major depressive patients
      with same genotypes had different clinical expression, including the severity of depression,
      with/without suicide, and the treatment response. Recently, some papers found that there were
      relationships between epigenetic regulation, including DNA methylation and histone
      modification, and psychopathology of major depression. Therefore, we try to investigate the
      relationships between epigenetic regulation of BDNF and major depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls</measure>
    <time_frame>2 years</time_frame>
    <description>averaged percentage of methylation at each CpG site listed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls</measure>
    <time_frame>2 years</time_frame>
    <description>Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O'Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365-369.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls</measure>
    <time_frame>2 years</time_frame>
    <description>Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Major depressive patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This 2-year study will be conducted in our clinical setting. By a semi-structured interview
        for DSM-IV criteria, a total of 160 subjectes (80 healthy controls and 80 patients with
        major depression) will be recruited in this study. In the first year (recruiting 40 healthy
        controls and 40 patients with major depression), the data of BDNF DNA methylation in all
        subjects will be collected. In the second year (recruiting another 40 healthy controls and
        40 patients with major depression), the data of BDNF histone modification in all subjects
        will be collected and the mechanism of epigenetic regulation of BDNF in major depression
        will be discussed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The clinical screening and assessment in patients with major depression：

          1. 40 major depression will be recruited in psychiatric inpatients according to DSM-IV
             criteria by a semi-structured interview. The assessment will be done by two senior
             psychiatrists. The intra-rater and inter-rater reliability will be done before this
             project started.

          2. The patients had the ability to complete the written inform consent.

          3. The choice of antidepressant drugs depended on the need of patients in natural
             treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg.
             fluoxetine or paroxetine.

          4. The 17-item Hamilton Depression Rating Scale (HAM-D) was used to assess severity of
             depression. The minimum baseline score of the 17-item HAM-D was 18.

        Exclusion Criteria:

          1. The patients had systemic diseases, including metabolic, heart, and liver diseases。

          2. The patients had received any drugs before entering this protocol.

          3. The patients were heavy smokers or dependent on alcohol.

          4. The use of secondary generation anti-psychotic drugs and mood stabilizers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiao-Lai Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital, Kaohsiung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <results_first_submitted>June 7, 2013</results_first_submitted>
  <results_first_submitted_qc>July 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Tiao-Lai Huang</investigator_full_name>
    <investigator_title>Head of Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Major depression</keyword>
  <keyword>BDNF</keyword>
  <keyword>DNA methylation</keyword>
  <keyword>Histone modification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From August 1st, 2000 to July 31st, 2012, major depressive disorder patients were recruited from Kaohsiung Chang Gung Memorial Hospital, a tertiary medical center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Major Depressive Patients</title>
        </group>
        <group group_id="P2">
          <title>Healthy Subjects</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Major Depressive Patients</title>
        </group>
        <group group_id="B2">
          <title>Healthy Subjects</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.44" spread="12.09"/>
                    <measurement group_id="B2" value="30.18" spread="5.6"/>
                    <measurement group_id="B3" value="35.53" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls</title>
        <description>averaged percentage of methylation at each CpG site listed</description>
        <time_frame>2 years</time_frame>
        <population>Only 39 out of the 48 MDD patients provided enough blood sample for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Major Depressive Patients</title>
          </group>
          <group group_id="O2">
            <title>Healthy Subjects</title>
          </group>
        </group_list>
        <measure>
          <title>Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls</title>
          <description>averaged percentage of methylation at each CpG site listed</description>
          <population>Only 39 out of the 48 MDD patients provided enough blood sample for this analysis.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CpG site 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="5.0"/>
                    <measurement group_id="O2" value="92" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="5.4"/>
                    <measurement group_id="O2" value="75" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="7.6"/>
                    <measurement group_id="O2" value="63" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="4.2"/>
                    <measurement group_id="O2" value="86" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="23.2"/>
                    <measurement group_id="O2" value="41" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 177</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="3.9"/>
                    <measurement group_id="O2" value="94" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 203</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="5.2"/>
                    <measurement group_id="O2" value="90" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 217</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="8.0"/>
                    <measurement group_id="O2" value="51" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="4.8"/>
                    <measurement group_id="O2" value="95" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 327</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="4.7"/>
                    <measurement group_id="O2" value="90" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 345</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" spread="5.0"/>
                    <measurement group_id="O2" value="98" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 348</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="6.0"/>
                    <measurement group_id="O2" value="91" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 362</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" spread="4.4"/>
                    <measurement group_id="O2" value="91" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CpG site 391</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="4.8"/>
                    <measurement group_id="O2" value="85" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls</title>
        <description>Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O’Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365–369.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subjects</title>
          </group>
          <group group_id="O2">
            <title>Major Depressive Patients Before Treatment</title>
          </group>
          <group group_id="O3">
            <title>Major Depressive Patients After Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls</title>
          <description>Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O’Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365–369.</description>
          <units>relative quantification</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDNF promotor I acetyl-H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5610" spread="2.79865"/>
                    <measurement group_id="O2" value=".3124" spread=".53231"/>
                    <measurement group_id="O3" value=".4321" spread=".32039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF promotor I acetyl-H4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6346" spread="2.66175"/>
                    <measurement group_id="O2" value=".3784" spread=".54543"/>
                    <measurement group_id="O3" value=".4659" spread=".62056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF promotor IV acetyl-H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6356" spread="2.33692"/>
                    <measurement group_id="O2" value=".4059" spread=".43157"/>
                    <measurement group_id="O3" value=".4303" spread=".70365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF promotor IV acetyl-H4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2795" spread="2.66175"/>
                    <measurement group_id="O2" value=".4676" spread=".54543"/>
                    <measurement group_id="O3" value=".4988" spread=".62056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF promotor X acetyl-H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8960" spread="1.94450"/>
                    <measurement group_id="O2" value=".2564" spread=".36703"/>
                    <measurement group_id="O3" value=".3640" spread=".34533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF promotor X acetyl-H4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7433" spread="2.66175"/>
                    <measurement group_id="O2" value=".2105" spread=".30502"/>
                    <measurement group_id="O3" value=".2540" spread=".53050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls</title>
        <description>Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subjects</title>
          </group>
          <group group_id="O2">
            <title>Major Depressive Patients Before Treatment</title>
          </group>
          <group group_id="O3">
            <title>Major Depressive Patients After Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls</title>
          <description>Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9386" spread="3.24400"/>
                    <measurement group_id="O2" value="5.6014" spread="4.46981"/>
                    <measurement group_id="O3" value="6.2803" spread="5.58535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Major Depressive Patients</title>
        </group>
        <group group_id="E2">
          <title>Healthy Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited funding prevented all samples from receiving all analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tiao-Lai Huang</name_or_title>
      <organization>Kaohsiung Chang Gung Memorial Hospital</organization>
      <phone>886-7-7317123 ext 8753</phone>
      <email>a540520@adm.cgmh.org.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

